MorphoSys (NASDAQ:MOR) Given New €37.00 Price Target

MorphoSys (NASDAQ:MOR – Get Rating) had its price target decreased by equities research analysts at Morgan Stanley from €40.00 ($41.67) to €37.00 ($38.54) in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has an “equal weight” rating on the stock. MOR has been the topic of a […]

Related Keywords

United States , , Capricorn Fund Managers Ltd , Morgan Stanley , Berenberg Bank , Zacks Investment Research , Deutsche Bank Aktiengesellschaft , Quadrant Capital Group , Cubist Systematic Strategies , Citigroup , Us Bancorp , Get Rating , Investment Research , Bank Aktiengesellschaft , Capital Group , Systematic Strategies , Morphosys , Nasdaq Mor , Humor , Medical , Lower Price Target ,